{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:44:10Z","timestamp":1790790250235,"version":"4.1.0"},"reference-count":125,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"vor","delay-in-days":685,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s13311-021-01154-y","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T17:03:40Z","timestamp":1638291820000},"page":"2286-2302","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Current and Emerging Therapies for Hereditary Transthyretin Amyloidosis: Strides Towards a Brighter Future"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7468-700X","authenticated-orcid":false,"given":"Laura","family":"Obici","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Mussinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1007\/s13311-021-01154-y_bib1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","article-title":"Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease","volume":"15","author":"Adams","year":"2019","journal-title":"Nat Rev Neurol."},{"issue":"9","key":"10.1007\/s13311-021-01154-y_bib2","doi-asserted-by":"crossref","first-page":"E2403","DOI":"10.1002\/humu.22619","article-title":"Online registry for mutations in hereditary amyloidosis including nomenclature recommendations","volume":"35","author":"Rowczenio","year":"2014","journal-title":"Hum Mutat."},{"issue":"5","key":"10.1007\/s13311-021-01154-y_bib3","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/mus.26034","article-title":"Estimating the global prevalence of transthyretin familial amyloid polyneuropathy","volume":"57","author":"Schmidt","year":"2018","journal-title":"Muscle Nerve."},{"issue":"5","key":"10.1007\/s13311-021-01154-y_bib4","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1136\/jnnp-2016-315262","article-title":"Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy","volume":"88","author":"Cortese","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"3","key":"10.1007\/s13311-021-01154-y_bib5","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/brain\/75.3.408","article-title":"A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves","volume":"75","author":"Andrade","year":"1952","journal-title":"Brain."},{"issue":"2","key":"10.1007\/s13311-021-01154-y_bib6","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/jns.12451","article-title":"The neuropathy in hereditary transthyretin amyloidosis: A narrative review","volume":"26","author":"Tozza","year":"2021","journal-title":"J Peripher Nerv Syst."},{"issue":"Suppl 1","key":"10.1007\/s13311-021-01154-y_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10286-019-00630-y","article-title":"Characteristics and natural history of autonomic involvement in hereditary ATTR amyloidosis: a systematic review","volume":"29","author":"Gonzalez-Duarte","year":"2019","journal-title":"Clin Auton Res."},{"key":"10.1007\/s13311-021-01154-y_bib8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1750-1172-9-61","article-title":"THAOS: gastrointestinal manifestations of transthyretin amyloidosis - common complications of a rare disease","volume":"9","author":"Wixner","year":"2014","journal-title":"Orphanet J Rare Dis."},{"issue":"Suppl 1","key":"10.1007\/s13311-021-01154-y_bib9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s10286-019-00628-6","article-title":"Diagnosis and treatment of gastrointestinal dysfunction in hereditary TTR amyloidosis","volume":"29","author":"Obici","year":"2019","journal-title":"Clin Auton Res."},{"issue":"6","key":"10.1007\/s13311-021-01154-y_bib10","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1007\/s00415-019-09688-0","article-title":"Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy","volume":"268","author":"Adams","year":"2021","journal-title":"J Neurol."},{"issue":"16","key":"10.1007\/s13311-021-01154-y_bib11","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"European heart journal."},{"issue":"30","key":"10.1007\/s13311-021-01154-y_bib12","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"European heart journal."},{"issue":"2","key":"10.1007\/s13311-021-01154-y_bib13","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jchf.2020.09.011","article-title":"Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT","volume":"9","author":"Rapezzi","year":"2021","journal-title":"JACC Heart Fail."},{"issue":"2","key":"10.1007\/s13311-021-01154-y_bib14","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.trre.2016.09.002","article-title":"Liver transplantation in transthyretin amyloidosis: Characteristics and management related to kidney disease","volume":"31","author":"Rocha","year":"2017","journal-title":"Transplant Rev (Orlando)."},{"issue":"6","key":"10.1007\/s13311-021-01154-y_bib15","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/joim.13222","article-title":"Transthyretin amyloid deposits in lumbar spinal stenosis and assessment of signs of systemic amyloidosis","volume":"289","author":"Eldhagen","year":"2021","journal-title":"J Intern Med."},{"issue":"6","key":"10.1007\/s13311-021-01154-y_bib16","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.nmd.2015.02.001","article-title":"Transthyretin V122I amyloidosis with clinical and histological evidence of amyloid neuropathy and myopathy","volume":"25","author":"Carr","year":"2015","journal-title":"Neuromuscul Disord."},{"key":"10.1007\/s13311-021-01154-y_bib17","doi-asserted-by":"crossref","unstructured":"Patel RK, Fontana M, Hawkins PN, Gillmore J. Splenic regression of amyloid on multi-modality imaging in response to treatment with patisiran and diflunisal in hereditary transthyretin amyloidosis. Amyloid. 2021:1\u20132\u00a0https:\/\/doi.org\/10.1080\/13506129.2021.1920389.","DOI":"10.1080\/13506129.2021.1920389"},{"issue":"2","key":"10.1007\/s13311-021-01154-y_bib18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3109\/13506129.2015.1015678","article-title":"Ophthalmological manifestations in hereditary transthyretin (ATTR V30M) carriers: a review of 513 cases","volume":"22","author":"Beirao","year":"2015","journal-title":"Amyloid."},{"issue":"2","key":"10.1007\/s13311-021-01154-y_bib19","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1136\/jnnp-2014-308107","article-title":"CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings","volume":"86","author":"Maia","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"8","key":"10.1007\/s13311-021-01154-y_bib20","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1212\/WNL.0000000000001870","article-title":"Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history study","volume":"85","author":"Adams","year":"2015","journal-title":"Neurology."},{"key":"10.1007\/s13311-021-01154-y_bib21","doi-asserted-by":"crossref","unstructured":"Lin X, Yarlas A, Vera-Llonch M, Baranwal N, Biber J, Brown D, et al. Rate of neuropathic progression in hereditary transthyretin amyloidosis with polyneuropathy and other peripheral neuropathies: a systematic review and meta-analysis. BMC Neurol. 2021;21 1:70\u00a0https:\/\/doi.org\/10.1186\/s12883-021-02094-y.","DOI":"10.1186\/s12883-021-02094-y"},{"issue":"3","key":"10.1007\/s13311-021-01154-y_bib22","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/13506129.2020.1730790","article-title":"Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis","volume":"27","author":"Obici","year":"2020","journal-title":"Amyloid."},{"issue":"2","key":"10.1007\/s13311-021-01154-y_bib23","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/mus.26515","article-title":"Burden of hereditary transthyretin amyloidosis on quality of life","volume":"60","author":"Yarlas","year":"2019","journal-title":"Muscle Nerve."},{"key":"10.1007\/s13311-021-01154-y_bib24","doi-asserted-by":"crossref","unstructured":"Magliano L, Obici L, Sforzini C, Mazzeo A, Russo M, Cappelli F, et al. Psychosocial burden and professional and social support in patients with hereditary transthyretin amyloidosis (ATTRv) and their relatives in Italy. Orphanet J Rare Dis. 2021;16 1:163\u00a0https:\/\/doi.org\/10.1186\/s13023-021-01812-6.","DOI":"10.1186\/s13023-021-01812-6"},{"key":"10.1007\/s13311-021-01154-y_bib25","doi-asserted-by":"crossref","unstructured":"Rintell D, Heath D, Braga Mendendez F, Cross E, Cross T, Knobel V, et al. Patient and family experience with transthyretin amyloid cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN) amyloidosis: results of two focus groups. Orphanet J Rare Dis. 2021;16 1:70\u00a0https:\/\/doi.org\/10.1186\/s13023-021-01706-7.","DOI":"10.1186\/s13023-021-01706-7"},{"key":"10.1007\/s13311-021-01154-y_bib26","doi-asserted-by":"crossref","unstructured":"Lovley A, Raymond K, Guthrie SD, Pollock M, Sanchorawala V, White MK. Patient-reported burden of hereditary transthyretin amyloidosis on functioning and well-being. J Patient Rep Outcomes. 2021;5 1:3\u00a0https:\/\/doi.org\/10.1186\/s41687-020-00273-y.","DOI":"10.1186\/s41687-020-00273-y"},{"key":"10.1007\/s13311-021-01154-y_bib27","doi-asserted-by":"crossref","unstructured":"Gonzalez-Moreno J, Gaya-Barroso A, Losada-Lopez I, Rodriguez A, Bosch-Rovira T, Ripoll-Vera T, et al. Val50Met hereditary transthyretin amyloidosis: not just a medical problem, but a psychosocial burden. Orphanet J Rare Dis. 2021;16 1:266\u00a0https:\/\/doi.org\/10.1186\/s13023-021-01910-5.","DOI":"10.1186\/s13023-021-01910-5"},{"issue":"36","key":"10.1007\/s13311-021-01154-y_bib28","doi-asserted-by":"crossref","first-page":"8654","DOI":"10.1021\/bi00151a036","article-title":"Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro","volume":"31","author":"Colon","year":"1992","journal-title":"Biochemistry."},{"issue":"29","key":"10.1007\/s13311-021-01154-y_bib29","doi-asserted-by":"crossref","first-page":"27207","DOI":"10.1074\/jbc.M101024200","article-title":"Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants","volume":"276","author":"Quintas","year":"2001","journal-title":"J Biol Chem."},{"issue":"24","key":"10.1007\/s13311-021-01154-y_bib30","doi-asserted-by":"crossref","first-page":"9629","DOI":"10.1073\/pnas.1121005109","article-title":"Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade","volume":"109","author":"Bulawa","year":"2012","journal-title":"Proceedings of the National Academy of Sciences of the United States of America."},{"issue":"2","key":"10.1007\/s13311-021-01154-y_bib31","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/path.1759","article-title":"Amyloid deposits in transthyretin-derived amyloidosis: cleaved transthyretin is associated with distinct amyloid morphology","volume":"206","author":"Bergstrom","year":"2005","journal-title":"J Pathol."},{"issue":"10","key":"10.1007\/s13311-021-01154-y_bib32","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.15252\/emmm.201505357","article-title":"A novel mechano-enzymatic cleavage mechanism underlies transthyretin amyloidogenesis","volume":"7","author":"Marcoux","year":"2015","journal-title":"EMBO Mol Med."},{"issue":"37","key":"10.1007\/s13311-021-01154-y_bib33","doi-asserted-by":"crossref","first-page":"14192","DOI":"10.1074\/jbc.RA118.003990","article-title":"Plasminogen activation triggers transthyretin amyloidogenesis in vitro","volume":"293","author":"Mangione","year":"2018","journal-title":"J Biol Chem."},{"issue":"25","key":"10.1007\/s13311-021-01154-y_bib34","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1021\/acs.biochem.0c00079","article-title":"Disruption of the CD Loop by Enzymatic Cleavage Promotes the Formation of Toxic Transthyretin Oligomers through a Common Transthyretin Misfolding Pathway","volume":"59","author":"Dasari","year":"2020","journal-title":"Biochemistry."},{"key":"10.1007\/s13311-021-01154-y_bib35","doi-asserted-by":"crossref","unstructured":"Peterle D, Pontarollo G, Spada S, Brun P, Palazzi L, Sokolov AV, et al. A serine protease secreted from Bacillus subtilis cleaves human plasma transthyretin to generate an amyloidogenic fragment. Commun Biol. 2020;3 1:764\u00a0https:\/\/doi.org\/10.1038\/s42003-020-01493-0.","DOI":"10.1038\/s42003-020-01493-0"},{"issue":"4","key":"10.1007\/s13311-021-01154-y_bib36","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1073\/pnas.1317488111","article-title":"Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis","volume":"111","author":"Mangione","year":"2014","journal-title":"Proceedings of the National Academy of Sciences of the United States of America."},{"key":"10.1007\/s13311-021-01154-y_bib37","doi-asserted-by":"crossref","unstructured":"Yee PP, Wei Y, Kim SY, Lu T, Chih SY, Lawson C, et al. Neutrophil-induced ferroptosis promotes tumor necrosis in glioblastoma progression. Nat Commun. 2020;11 1:5424\u00a0https:\/\/doi.org\/10.1038\/s41467-020-19193-y.","DOI":"10.1038\/s41467-020-19193-y"},{"issue":"28","key":"10.1007\/s13311-021-01154-y_bib38","first-page":"E6428","article-title":"Unusual duplication mutation in a surface loop of human transthyretin leads to an aggressive drug-resistant amyloid disease","volume":"115","author":"Klimtchuk","year":"2018","journal-title":"Proceedings of the National Academy of Sciences of the United States of America."},{"issue":"29","key":"10.1007\/s13311-021-01154-y_bib39","first-page":"E6741","article-title":"Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition","volume":"115","author":"Saelices","year":"2018","journal-title":"Proceedings of the National Academy of Sciences of the United States of America."},{"issue":"1","key":"10.1007\/s13311-021-01154-y_bib40","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ajpath.2010.11.015","article-title":"Evidence for a functional role of the molecular chaperone clusterin in amyloidotic cardiomyopathy","volume":"178","author":"Greene","year":"2011","journal-title":"Am J Pathol."},{"issue":"12","key":"10.1007\/s13311-021-01154-y_bib41","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1097\/NEN.0b013e31823a44f4","article-title":"Clusterin overexpression and its possible protective role in transthyretin deposition in familial amyloidotic polyneuropathy","volume":"70","author":"Magalh\u00e3es","year":"2011","journal-title":"J Neuropathol Exp Neurol."},{"issue":"2","key":"10.1007\/s13311-021-01154-y_bib42","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1021\/bi5011249","article-title":"Cooperative stabilization of transthyretin by clusterin and diflunisal","volume":"54","author":"Greene","year":"2015","journal-title":"Biochemistry."},{"issue":"8","key":"10.1007\/s13311-021-01154-y_bib43","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/labinvest.2013.83","article-title":"Fibroblasts endocytose and degrade transthyretin aggregates in transthyretin-related amyloidosis","volume":"93","author":"Misumi","year":"2013","journal-title":"Lab Invest."},{"key":"10.1007\/s13311-021-01154-y_bib44","doi-asserted-by":"crossref","unstructured":"Sousa MM, do Amaral JB, Guimar\u00e3es A, Saraiva MJ. Up-regulation of the extracellular matrix remodeling genes, biglycan, neutrophil gelatinase-associated lipocalin, and matrix metalloproteinase-9 in familial amyloid polyneuropathy. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2005;19 1:124\u20136\u00a0https:\/\/doi.org\/10.1096\/fj.04-2022fje.","DOI":"10.1096\/fj.04-2022fje"},{"issue":"3","key":"10.1007\/s13311-021-01154-y_bib45","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/sj.ejhg.5201095","article-title":"Haplotypes and DNA sequence variation within and surrounding the transthyretin gene: genotype-phenotype correlations in familial amyloid polyneuropathy (V30M) in Portugal and Sweden","volume":"12","author":"Soares","year":"2004","journal-title":"Eur J Hum Genet."},{"issue":"4","key":"10.1007\/s13311-021-01154-y_bib46","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/hmg\/ddi051","article-title":"Susceptibility and modifier genes in Portuguese transthyretin V30M amyloid polyneuropathy: complexity in a single-gene disease","volume":"14","author":"Soares","year":"2005","journal-title":"Hum Mol Genet."},{"issue":"9","key":"10.1007\/s13311-021-01154-y_bib47","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/ejhg.2017.95","article-title":"Non-coding variants contribute to the clinical heterogeneity of TTR amyloidosis","volume":"25","author":"Iorio","year":"2017","journal-title":"Eur J Hum Genet."},{"issue":"2","key":"10.1007\/s13311-021-01154-y_bib48","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1080\/13506129.2020.1857236","article-title":"Beyond Val30Met transthyretin (TTR): variants associated with age-at-onset in hereditary ATTRv amyloidosis","volume":"28","author":"Alves-Ferreira","year":"2021","journal-title":"Amyloid."},{"issue":"4","key":"10.1007\/s13311-021-01154-y_bib49","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/acn3.748","article-title":"C1QA and C1QC modify age-at-onset in familial amyloid polyneuropathy patients","volume":"6","author":"Dias","year":"2019","journal-title":"Ann Clin Transl Neurol."},{"issue":"5","key":"10.1007\/s13311-021-01154-y_bib50","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/ejhg.2015.180","article-title":"Variants in RBP4 and AR genes modulate age at onset in familial amyloid polyneuropathy (FAP ATTRV30M)","volume":"24","author":"Santos","year":"2016","journal-title":"Eur J Hum Genet."},{"key":"10.1007\/s13311-021-01154-y_bib51","doi-asserted-by":"crossref","unstructured":"De Lillo A, Pathak GA, De Angelis F, Di Girolamo M, Luigetti M, Sabatelli M, et al. Epigenetic profiling of Italian patients identified methylation sites associated with hereditary transthyretin amyloidosis. Clin Epigenetics. 2020;12 1:176\u00a0https:\/\/doi.org\/10.1186\/s13148-020-00967-6.","DOI":"10.1186\/s13148-020-00967-6"},{"issue":"9","key":"10.1007\/s13311-021-01154-y_bib52","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/TP.0000000000000574","article-title":"Liver Transplantation for Hereditary Transthyretin Amyloidosis: After 20 Years Still the Best Therapeutic Alternative?","volume":"99","author":"Ericzon","year":"2015","journal-title":"Transplantation."},{"issue":"1","key":"10.1007\/s13311-021-01154-y_bib53","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1474-4422(20)30368-9","article-title":"Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study","volume":"20","author":"Adams","year":"2021","journal-title":"Lancet Neurol."},{"issue":"8","key":"10.1007\/s13311-021-01154-y_bib54","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1111\/ene.14285","article-title":"Early data on long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2-year update from the open-label extension of the NEURO-TTR trial","volume":"27","author":"Brannagan","year":"2020","journal-title":"Eur J Neurol."},{"issue":"3","key":"10.1007\/s13311-021-01154-y_bib55","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1080\/13506129.2017.1357545","article-title":"Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years","volume":"24","author":"Barroso","year":"2017","journal-title":"Amyloid."},{"issue":"1","key":"10.1007\/s13311-021-01154-y_bib56","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood.2019004460","article-title":"Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA","volume":"136","author":"Palladini","year":"2020","journal-title":"Blood."},{"issue":"23","key":"10.1007\/s13311-021-01154-y_bib57","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1056\/NEJMoa070265","article-title":"Natural history and outcome in systemic AA amyloidosis","volume":"356","author":"Lachmann","year":"2007","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1007\/s13311-021-01154-y_bib58","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1007\/s13311-021-01154-y_bib59","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med."},{"key":"10.1007\/s13311-021-01154-y_bib60","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis","author":"Gillmore","year":"2021","journal-title":"N Engl J Med."},{"issue":"4","key":"10.1007\/s13311-021-01154-y_bib61","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1007\/s00415-019-09671-9","article-title":"Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis","volume":"267","author":"Coelho","year":"2020","journal-title":"J Neurol."},{"issue":"2","key":"10.1007\/s13311-021-01154-y_bib62","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1089\/nat.2019.0829","article-title":"Underlying Immune Disorder May Predispose Some Transthyretin Amyloidosis Subjects to Inotersen-Mediated Thrombocytopenia","volume":"30","author":"Narayanan","year":"2020","journal-title":"Nucleic Acid Ther."},{"issue":"5","key":"10.1007\/s13311-021-01154-y_bib63","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1089\/nat.2020.0867","article-title":"Immunogenicity Assessment of Inotersen, a 2'-O-(2-Methoxyethyl) Antisense Oligonucleotide in Animals and Humans: Effect on Pharmacokinetics, Pharmacodynamics, and Safety","volume":"30","author":"Yu","year":"2020","journal-title":"Nucleic Acid Ther."},{"key":"10.1007\/s13311-021-01154-y_bib64","unstructured":"Coelho: Efficacy and Safety With >3 Years of Inotersen Treatment for the Polyneuropathy of Hereditary Transthyretin Amyloidosis In: European Acad Neurol. 2021."},{"issue":"4","key":"10.1007\/s13311-021-01154-y_bib65","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1080\/13506129.2020.1784134","article-title":"TTR gene silencing therapy in post liver transplant hereditary ATTR amyloidosis patients","volume":"27","author":"Moshe-Lilie","year":"2020","journal-title":"Amyloid."},{"issue":"1","key":"10.1007\/s13311-021-01154-y_bib66","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/ehf2.13154","article-title":"Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data","volume":"8","author":"Viney","year":"2021","journal-title":"ESC Heart Fail."},{"issue":"1","key":"10.1007\/s13311-021-01154-y_bib67","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s40120-021-00235-6","article-title":"Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy","volume":"10","author":"Coelho","year":"2021","journal-title":"Neurol Ther."},{"issue":"24","key":"10.1007\/s13311-021-01154-y_bib68","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","article-title":"Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria","volume":"382","author":"Balwani","year":"2020","journal-title":"N Engl J Med."},{"issue":"13","key":"10.1007\/s13311-021-01154-y_bib69","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","article-title":"Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1","volume":"384","author":"Garrelfs","year":"2021","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1007\/s13311-021-01154-y_bib70","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/jcph.1480","article-title":"Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure-Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin-Mediated (hATTR) Amyloidosis","volume":"60","author":"Zhang","year":"2020","journal-title":"J Clin Pharmacol."},{"key":"10.1007\/s13311-021-01154-y_bib71","doi-asserted-by":"crossref","unstructured":"Amanda Peltier AG-D, John Berk, Ivailo Tournev, Ole Suhr, Senda Ajroud-Driss, Madeline Merkel, Hollis Lin, Cecilia Hale, David Adams: Impact of Patisiran on Activities of Daily Living and Functional Status in hATTR Amyloidosis In: AAN. vol. 96: Neurology; 2021.","DOI":"10.1212\/WNL.96.15_supplement.1493"},{"issue":"3","key":"10.1007\/s13311-021-01154-y_bib72","doi-asserted-by":"crossref","first-page":"e412","DOI":"10.1212\/WNL.0000000000011090","article-title":"Neurofilament Light Chain as a Biomarker of Hereditary Transthyretin-Mediated Amyloidosis","volume":"96","author":"Ticau","year":"2021","journal-title":"Neurology."},{"key":"10.1007\/s13311-021-01154-y_bib73","doi-asserted-by":"crossref","unstructured":"Polydefkis: Neurofilament Light Chain (NfL) as a Potential Biomarker of Treatment Response in Hereditary Transthyretin-Mediated Amyloidosis: Data from the Patisiran Global OLE Study In., vol. 96, Neurology edn; 2021.","DOI":"10.1212\/WNL.96.15_supplement.1291"},{"issue":"4","key":"10.1007\/s13311-021-01154-y_bib74","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation."},{"issue":"5","key":"10.1007\/s13311-021-01154-y_bib75","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1001\/jamacardio.2019.0849","article-title":"Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis: The APOLLO Study","volume":"4","author":"Minamisawa","year":"2019","journal-title":"JAMA Cardiol."},{"key":"10.1007\/s13311-021-01154-y_bib76","unstructured":"Francisco Mu\u00f1oz-Beamud TC, Julian D Gillmore, Anna Mazzeo, Jonas Wixner, Violaine Plant\u00e9-Bordeneuve, Laura Llad\u00f3, Seth Arum, Matthew T White, Patrick Y Jay, David Adams: Patisiran in Patients with hATTR Amyloidosis Post-Orthotopic Liver Transplant: 12-Month Results. In: Peripheral Nerve Society (PNS) Annual Meeting."},{"key":"10.1007\/s13311-021-01154-y_bib77","doi-asserted-by":"crossref","unstructured":"David Adams ILT, Mark S Taylor, Teresa Coelho, Violaine Plant\u00e9-Bordeneuve, John L Berk, Alejandra Gonz\u00e1lez-Duarte, Julian D Gillmore, Soon-Chai Low, Yoshiki Sekijima, Laura Obici, Rick Blakesley, Seth Arum, Rebecca Shilling, John Vest, Michael Polydefkis: HELIOS-A: 9-month Results from the Phase 3 Study of Vutrisiran in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy. In: AAN. vol. 96: Neurology; 2021.","DOI":"10.1212\/WNL.96.15_supplement.1234"},{"issue":"5539","key":"10.1007\/s13311-021-01154-y_bib78","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1126\/science.1062245","article-title":"Trans-suppression of misfolding in an amyloid disease","volume":"293","author":"Hammarstrom","year":"2001","journal-title":"Science."},{"issue":"17","key":"10.1007\/s13311-021-01154-y_bib79","doi-asserted-by":"crossref","first-page":"8274","DOI":"10.1021\/acs.jmedchem.9b01037","article-title":"Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes","volume":"62","author":"Corazza","year":"2019","journal-title":"Journal of medicinal chemistry."},{"key":"10.1007\/s13311-021-01154-y_bib80","doi-asserted-by":"crossref","unstructured":"Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Plante-Bordeneuve V, Lozeron P, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79 8:785\u201392\u00a0https:\/\/doi.org\/10.1212\/WNL.0b013e3182661eb1.","DOI":"10.1212\/WNL.0b013e3182661eb1"},{"issue":"11","key":"10.1007\/s13311-021-01154-y_bib81","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1007\/s00415-013-7051-7","article-title":"Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy","volume":"260","author":"Coelho","year":"2013","journal-title":"J Neurol."},{"key":"10.1007\/s13311-021-01154-y_bib82","doi-asserted-by":"crossref","unstructured":"Waddington Cruz M, Amass L, Keohane D, Schwartz J, Li H, Gundapaneni B. Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy. Amyloid. 2016;23 3:178\u201383\u00a0https:\/\/doi.org\/10.1080\/13506129.2016.1207163.","DOI":"10.1080\/13506129.2016.1207163"},{"issue":"4","key":"10.1007\/s13311-021-01154-y_bib83","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/13506129.2019.1643714","article-title":"A comprehensive safety profile of tafamidis in patients with transthyretin amyloid polyneuropathy","volume":"26","author":"Huber","year":"2019","journal-title":"Amyloid."},{"issue":"11","key":"10.1007\/s13311-021-01154-y_bib84","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/ene.13724","article-title":"Hereditary amyloidosis related to transthyretin V30M: disease progression in treated and untreated patients","volume":"25","author":"Conceicao","year":"2018","journal-title":"Eur J Neurol."},{"key":"10.1007\/s13311-021-01154-y_bib85","doi-asserted-by":"crossref","unstructured":"Monteiro C, Mesgazardeh JS, Anselmo J, Fernandes J, Novais M, Rodrigues C, et al. Predictive model of response to tafamidis in hereditary ATTR polyneuropathy. JCI Insight. 2019;4 12\u00a0https:\/\/doi.org\/10.1172\/jci.insight.126526.","DOI":"10.1172\/jci.insight.126526"},{"issue":"21","key":"10.1007\/s13311-021-01154-y_bib86","doi-asserted-by":"crossref","first-page":"e1999","DOI":"10.1212\/WNL.0000000000006543","article-title":"Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy","volume":"91","author":"Coelho","year":"2018","journal-title":"Neurology."},{"issue":"5","key":"10.1007\/s13311-021-01154-y_bib87","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1007\/s00415-016-8064-9","article-title":"Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area","volume":"263","author":"Cortese","year":"2016","journal-title":"J Neurol."},{"issue":"12","key":"10.1007\/s13311-021-01154-y_bib88","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1111\/ene.12225","article-title":"Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy","volume":"20","author":"Lozeron","year":"2013","journal-title":"Eur J Neurol."},{"issue":"2","key":"10.1007\/s13311-021-01154-y_bib89","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s00415-016-8337-3","article-title":"Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study","volume":"264","author":"Plante-Bordeneuve","year":"2017","journal-title":"J Neurol."},{"key":"10.1007\/s13311-021-01154-y_bib90","doi-asserted-by":"crossref","unstructured":"Jiang X, Labaudiniere R, Buxbaum JN, Monteiro C, Novais M, Coelho T, et al. A circulating, disease-specific, mechanism-linked biomarker for ATTR polyneuropathy diagnosis and response to therapy prediction. Proceedings of the National Academy of Sciences of the United States of America. 2021;118 9\u00a0https:\/\/doi.org\/10.1073\/pnas.2016072118.","DOI":"10.1073\/pnas.2016072118"},{"issue":"3","key":"10.1007\/s13311-021-01154-y_bib91","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3109\/13506129.2015.1063485","article-title":"Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy)","volume":"22","author":"Cho","year":"2015","journal-title":"Amyloid."},{"key":"10.1007\/s13311-021-01154-y_bib92","doi-asserted-by":"crossref","unstructured":"Verona G, Mangione PP, Raimondi S, Giorgetti S, Faravelli G, Porcari R, et al. Inhibition of the mechano-enzymatic amyloidogenesis of transthyretin: role of ligand affinity, binding cooperativity and occupancy of the inner channel. Sci Rep. 2017;7 1:182\u00a0https:\/\/doi.org\/10.1038\/s41598-017-00338-x.","DOI":"10.1038\/s41598-017-00338-x"},{"issue":"11","key":"10.1007\/s13311-021-01154-y_bib93","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med."},{"issue":"7","key":"10.1007\/s13311-021-01154-y_bib94","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/cpdd.789","article-title":"The Bioequivalence of Tafamidis 61-mg Free Acid Capsules and Tafamidis Meglumine 4 x 20-mg Capsules in Healthy Volunteers","volume":"9","author":"Lockwood","year":"2020","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"2","key":"10.1007\/s13311-021-01154-y_bib95","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ejhf.2027","article-title":"Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study","volume":"23","author":"Damy","year":"2021","journal-title":"Eur J Heart Fail."},{"issue":"2","key":"10.1007\/s13311-021-01154-y_bib96","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/ejhf.2111","article-title":"New effective treatment options reinforce disease awareness: the case of transthyretin cardiac amyloidosis","volume":"23","author":"Perlini","year":"2021","journal-title":"Eur J Heart Fail."},{"issue":"24","key":"10.1007\/s13311-021-01154-y_bib97","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA."},{"issue":"4","key":"10.1007\/s13311-021-01154-y_bib98","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1080\/13506120600960882","article-title":"Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis","volume":"13","author":"Sekijima","year":"2006","journal-title":"Amyloid."},{"issue":"2","key":"10.1007\/s13311-021-01154-y_bib99","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/13506129.2014.997872","article-title":"Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis","volume":"22","author":"Sekijima","year":"2015","journal-title":"Amyloid."},{"issue":"1\u20132","key":"10.1007\/s13311-021-01154-y_bib100","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jns.2014.07.017","article-title":"Efficacy of diflunisal on autonomic dysfunction of late-onset familial amyloid polyneuropathy (TTR Val30Met) in a Japanese endemic area","volume":"345","author":"Takahashi","year":"2014","journal-title":"J Neurol Sci."},{"key":"10.1007\/s13311-021-01154-y_bib101","doi-asserted-by":"crossref","unstructured":"Rosenblum H, Castano A, Alvarez J, Goldsmith J, Helmke S, Maurer MS. TTR (Transthyretin) Stabilizers Are Associated With Improved Survival in Patients With TTR Cardiac Amyloidosis. Circ Heart Fail. 2018;11 4:e004769\u00a0https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.117.004769.","DOI":"10.1161\/CIRCHEARTFAILURE.117.004769"},{"key":"10.1007\/s13311-021-01154-y_bib102","first-page":"1","article-title":"Left ventricular deformation and torsion assessed by speckle-tracking echocardiography in patients with mutated transthyretin-associated cardiac amyloidosis and the effect of diflunisal on myocardial function","volume":"9","author":"Koyama","year":"2015","journal-title":"Int J Cardiol Heart Vasc."},{"issue":"9","key":"10.1007\/s13311-021-01154-y_bib103","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.cardfail.2019.11.024","article-title":"Stabilization of Cardiac Function With Diflunisal in Transthyretin (ATTR) Cardiac Amyloidosis","volume":"26","author":"Lohrmann","year":"2020","journal-title":"J Card Fail."},{"key":"10.1007\/s13311-021-01154-y_bib104","article-title":"The use of diflunisal for transthyretin cardiac amyloidosis: a review","author":"Ibrahim","year":"2021","journal-title":"Heart Fail Rev."},{"issue":"24","key":"10.1007\/s13311-021-01154-y_bib105","doi-asserted-by":"crossref","first-page":"9992","DOI":"10.1073\/pnas.1300761110","article-title":"AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin","volume":"110","author":"Penchala","year":"2013","journal-title":"Proceedings of the National Academy of Sciences of the United States of America."},{"issue":"3","key":"10.1007\/s13311-021-01154-y_bib106","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","article-title":"Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy","volume":"74","author":"Judge","year":"2019","journal-title":"Journal of the American College of Cardiology."},{"key":"10.1007\/s13311-021-01154-y_bib107","doi-asserted-by":"crossref","first-page":"10787","DOI":"10.1038\/ncomms10787","article-title":"Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity","volume":"7","author":"Sant'Anna","year":"2016","journal-title":"Nat Commun."},{"issue":"2","key":"10.1007\/s13311-021-01154-y_bib108","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/13506129.2019.1597702","article-title":"Transthyretin stabilization activity of the catechol-O-methyltransferase inhibitor tolcapone (SOM0226) in hereditary ATTR amyloidosis patients and asymptomatic carriers: proof-of-concept study","volume":"26","author":"Gamez","year":"2019","journal-title":"Amyloid."},{"issue":"1","key":"10.1007\/s13311-021-01154-y_bib109","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/febs.15339","article-title":"Tolcapone, a potent aggregation inhibitor for the treatment of familial leptomeningeal amyloidosis","volume":"288","author":"Pinheiro","year":"2021","journal-title":"FEBS J."},{"issue":"12","key":"10.1007\/s13311-021-01154-y_bib110","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMoa1504942","article-title":"Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component","volume":"373","author":"Richards","year":"2015","journal-title":"N Engl J Med."},{"issue":"2","key":"10.1007\/s13311-021-01154-y_bib111","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3109\/13506129.2016.1148025","article-title":"Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin","volume":"23","author":"Higaki","year":"2016","journal-title":"Amyloid."},{"key":"10.1007\/s13311-021-01154-y_bib112","unstructured":"Suhr: Neurological and cardiac improvements with PRX004 in TTR amyloidosis patients: results of a phase 1 study. In: AAN. vol. 96: Neurology; 2021."},{"key":"10.1007\/s13311-021-01154-y_bib113","doi-asserted-by":"crossref","unstructured":"Michalon A, Hagenbuch A, Huy C, Varela E, Combaluzier B, Damy T, et al. A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells. Nat Commun. 2021;12 1:3142\u00a0https:\/\/doi.org\/10.1038\/s41467-021-23274-x.","DOI":"10.1038\/s41467-021-23274-x"},{"issue":"3","key":"10.1007\/s13311-021-01154-y_bib114","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S0014-5793(00)02380-2","article-title":"Anti-amyloidogenic activity of tetracyclines: studies in vitro","volume":"487","author":"Forloni","year":"2001","journal-title":"FEBS letters."},{"issue":"2","key":"10.1007\/s13311-021-01154-y_bib115","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.nbd.2010.07.002","article-title":"Tetracycline and its analogues protect Caenorhabditis elegans from \u03b2 amyloid-induced toxicity by targeting oligomers","volume":"40","author":"Diomede","year":"2010","journal-title":"Neurobiol Dis."},{"issue":"2","key":"10.1007\/s13311-021-01154-y_bib116","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1096\/fj.05-4509com","article-title":"Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model","volume":"20","author":"Cardoso","year":"2006","journal-title":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology."},{"key":"10.1007\/s13311-021-01154-y_bib117","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1479-5876-8-74","article-title":"Synergy of combined doxycycline\/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models","volume":"8","author":"Cardoso","year":"2010","journal-title":"J Transl Med."},{"issue":"Suppl 1","key":"10.1007\/s13311-021-01154-y_bib118","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/13506129.2012.678508","article-title":"Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study","volume":"19","author":"Obici","year":"2012","journal-title":"Amyloid."},{"key":"10.1007\/s13311-021-01154-y_bib119","doi-asserted-by":"crossref","unstructured":"Coelho T, Adams D, Concei\u00e7\u00e3o I, Waddington-Cruz M, Schmidt HH, Buades J, et al. A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis. Orphanet J Rare Dis. 2020;15 1:179\u00a0https:\/\/doi.org\/10.1186\/s13023-020-01399-4.","DOI":"10.1186\/s13023-020-01399-4"},{"issue":"1","key":"10.1007\/s13311-021-01154-y_bib120","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jcmg.2020.07.043","article-title":"Reduction in CMR Derived Extracellular Volume With Patisiran Indicates Cardiac Amyloid Regression","volume":"14","author":"Fontana","year":"2021","journal-title":"JACC Cardiovasc Imaging."},{"key":"10.1007\/s13311-021-01154-y_bib121","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13023-015-0326-6","article-title":"Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study","volume":"10","author":"Suhr","year":"2015","journal-title":"Orphanet J Rare Dis."},{"key":"10.1007\/s13311-021-01154-y_bib122","doi-asserted-by":"crossref","unstructured":"Adams D, Suhr OB, Hund E, Obici L, Tournev I, Campistol JM, et al. First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol. 2016;29 Suppl 1 Suppl 1:S14\u201326\u00a0https:\/\/doi.org\/10.1097\/wco.0000000000000289.","DOI":"10.1097\/WCO.0000000000000289"},{"key":"10.1007\/s13311-021-01154-y_bib123","doi-asserted-by":"crossref","unstructured":"Obici L, Kuks JB, Buades J, Adams D, Suhr OB, Coelho T, et al. Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis. Curr Opin Neurol. 2016;29 Suppl 1 Suppl 1:S27\u201335\u00a0https:\/\/doi.org\/10.1097\/wco.0000000000000290.","DOI":"10.1097\/WCO.0000000000000290"},{"issue":"1","key":"10.1007\/s13311-021-01154-y_bib124","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1185\/03007995.2012.754348","article-title":"THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis","volume":"29","author":"Coelho","year":"2013","journal-title":"Curr Med Res Opin."},{"issue":"2","key":"10.1007\/s13311-021-01154-y_bib125","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s40120-020-00217-0","article-title":"A Narrative Review of the Role of Transthyretin in Health and Disease","volume":"9","author":"Liz","year":"2020","journal-title":"Neurol Ther."}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-021-01154-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-021-01154-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923007031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923007031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-021-01154-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:40:50Z","timestamp":1761806450000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923007031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":125,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S1878747923007031"],"URL":"https:\/\/doi.org\/10.1007\/s13311-021-01154-y","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current and Emerging Therapies for Hereditary Transthyretin Amyloidosis: Strides Towards a Brighter Future","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-021-01154-y","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}